Volume 30, Number 9—September 2024
Research
Medical Costs of Nontuberculous Mycobacterial Pulmonary Disease, South Korea, 2015–2019
Table 6
Model no., variable(s) | B | SE | β | t | p value | R2 | Adjusted R2 |
---|---|---|---|---|---|---|---|
1 | |||||||
No. admissions |
6058.547 |
627.484 |
0.785 |
9.655 |
<0.001 |
0.616 |
0.610 |
2 | 0.739 | 0.730 | |||||
No. admissions | 5503.292 | 532.913 | 0.713 | 10.327 | <0.001 | ||
Causative species: MAC = 0, M. abscessus = 1 |
7921.642 |
1530.022 |
0.358 |
5.177 |
<0.001 |
||
3 | 0.758 | 0.746 | |||||
No. admissions | 5379.334 | 520.642 | 0.697 | 10.332 | <0.001 | ||
Causative species: MAC = 0, M. abscessus = 1 | 7445.211 | 1502.260 | 0.336 | 4.956 | <0.001 | ||
Culture conversion | −3082.792 | 1455.967 | −0.142 | −2.117 | 0.039 |
*N = 147 patients. Variables include age, sex, history of tuberculosis, history of nontuberculous mycobacteria treatment, bronchiectasis, asthma, chronic obstructive pulmonary disease, lung cancer, causative species (MAC vs. M. abscessus), total follow-up duration, treatment duration, number of outpatient visits, number of admissions, culture conversion, microbiologic cure, retreatment for recurrence, and death from any cause. MAC, Mycobacterium avium complex; NA, not applicable.
1These first authors contributed equally to this article.
2These authors were co–principal investigators.
Page created: July 30, 2024
Page updated: August 22, 2024
Page reviewed: August 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.